BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28993503)

  • 1.
    Cechova S; Dong F; Chan F; Kelley MJ; Ruiz P; Le TH
    J Am Soc Nephrol; 2018 Jan; 29(1):155-167. PubMed ID: 28993503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy.
    Johnstone DB; Zhang J; George B; Léon C; Gachet C; Wong H; Parekh R; Holzman LB
    Mol Cell Biol; 2011 May; 31(10):2162-70. PubMed ID: 21402784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease.
    Kang JS; Lee SJ; Lee JH; Kim JH; Son SS; Cha SK; Lee ES; Chung CH; Lee EY
    Sci Rep; 2019 May; 9(1):7679. PubMed ID: 31118506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in non-muscle myosin 2A disrupt the actomyosin cytoskeleton in Sertoli cells and cause male infertility.
    Sung DC; Ahmad M; Lerma Cervantes CB; Zhang Y; Adelstein RS; Ma X
    Dev Biol; 2021 Feb; 470():49-61. PubMed ID: 33188738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
    Zhang Y; Conti MA; Malide D; Dong F; Wang A; Shmist YA; Liu C; Zerfas P; Daniels MP; Chan CC; Kozin E; Kachar B; Kelley MJ; Kopp JB; Adelstein RS
    Blood; 2012 Jan; 119(1):238-50. PubMed ID: 21908426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
    Suzuki N; Kunishima S; Ikejiri M; Maruyama S; Sone M; Takagi A; Ikawa M; Okabe M; Kojima T; Saito H; Naoe T; Matsushita T
    PLoS One; 2013; 8(8):e71187. PubMed ID: 23976996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Background strain and the differential susceptibility of podocyte-specific deletion of Myh9 on murine models of experimental glomerulosclerosis and HIV nephropathy.
    Johnstone DB; Ikizler O; Zhang J; Holzman LB
    PLoS One; 2013; 8(7):e67839. PubMed ID: 23874454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome).
    Ghiggeri GM; Caridi G; Magrini U; Sessa A; Savoia A; Seri M; Pecci A; Romagnoli R; Gangarossa S; Noris P; Sartore S; Necchi V; Ravazzolo R; Balduini CL
    Am J Kidney Dis; 2003 Jan; 41(1):95-104. PubMed ID: 12500226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin System Blockade Therapy for Early Renal Involvement in MYH9-related Disease with an E1841K Mutation.
    Tanaka M; Miki S; Saita H; Shimada H; Nishikawa S; Taniguchi K; Hagihara K; Iwanari S; Ikeda M; Kunishima S; Takeoka H
    Intern Med; 2019 Oct; 58(20):2983-2988. PubMed ID: 31243205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-muscle myosin-IIA is critical for podocyte f-actin organization, contractility, and attenuation of cell motility.
    Bondzie PA; Chen HA; Cao MZ; Tomolonis JA; He F; Pollak MR; Henderson JM
    Cytoskeleton (Hoboken); 2016 Aug; 73(8):377-95. PubMed ID: 27232264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
    Hayashi K; Sasamura H; Nakamura M; Sakamaki Y; Azegami T; Oguchi H; Tokuyama H; Wakino S; Hayashi K; Itoh H
    Kidney Int; 2015 Oct; 88(4):745-53. PubMed ID: 26108068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective VWF secretion due to expression of MYH9-RD E1841K mutant in endothelial cells disrupts hemostasis.
    Cao Y; Sun Y; Deng Y; Wei G; Liu J; Jin S; Dong C; Kang X; Huo Y; Zhang J; Luo J
    Blood Adv; 2022 Aug; 6(15):4537-4552. PubMed ID: 35764499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of γ-adducin in actin cytoskeleton rearrangements in podocyte pathophysiology.
    Gao W; Liu Y; Fan L; Zheng B; Jefferson JR; Wang S; Zhang H; Fang X; Nguyen BV; Zhu T; Roman RJ; Fan F
    Am J Physiol Renal Physiol; 2021 Jan; 320(1):F97-F113. PubMed ID: 33308016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study.
    Freedman BI; Kopp JB; Winkler CA; Nelson GW; Rao DC; Eckfeldt JH; Leppert MF; Hicks PJ; Divers J; Langefeld CD; Hunt SC
    Am J Nephrol; 2009; 29(6):626-32. PubMed ID: 19153477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis.
    Miura K; Kurihara H; Horita S; Chikamoto H; Hattori M; Harita Y; Tsurumi H; Kajiho Y; Sawada Y; Sasaki S; Igarashi T; Kunishima S; Sekine T
    Nephrol Dial Transplant; 2013 Dec; 28(12):2993-3003. PubMed ID: 24042022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes.
    Babayeva S; Miller M; Zilber Y; El Kares R; Bernard C; Bitzan M; Goodyer P; Torban E
    Pediatr Nephrol; 2011 Jul; 26(7):1071-81. PubMed ID: 21380797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
    Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
    Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.
    Tzur S; Rosset S; Shemer R; Yudkovsky G; Selig S; Tarekegn A; Bekele E; Bradman N; Wasser WG; Behar DM; Skorecki K
    Hum Genet; 2010 Sep; 128(3):345-50. PubMed ID: 20635188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.
    Pecci A; Ma X; Savoia A; Adelstein RS
    Gene; 2018 Jul; 664():152-167. PubMed ID: 29679756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.